NFKBIE: A Potential Drug Target for Neurodegenerative Diseases

Target Name: NFKBIE

NCBI ID: G4794

NFKBIE

NFKBIE: A Potential Drug Target for Neurodegenerative Diseases

The term \"IKBE\" refers to a protein that is expressed in the brain and is known to play a role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein, known as NFKBIE (N-cadherin-associated protein E), has been identified as a potential drug target for the treatment of these disorders.

The NFKBIE protein is a member of the cadherin family, which is a group of transmembrane proteins that play a critical role in cell-cell adhesion. Cadherins are involved in many important physiological processes in the body, including cell growth, differentiation, and survival. The NFKBIE protein is specifically involved in the regulation of cell adhesion and the maintenance of the blood-brain barrier.

One of the key functions of NFKBIE is its role in the development and progression of neurodegenerative diseases. Alzheimer's disease is a well-known example of such a disease, and it is characterized by the progressive accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain. The NFKBIE protein has been shown to be involved in the production of these hallmark hallucinations of Alzheimer's disease, as well as the progression of neurodegeneration.

In addition to its role in the development of neurodegenerative diseases, NFKBIE has also been shown to be involved in the regulation of normal brain function. For example, the NFKBIE protein has been shown to play a role in the regulation of neurotransmitter release from neurons, which is important for normal brain function.

The potential drug target for NFKBIE is its ability to modulate the activity of other proteins involved in the development and progression of neurodegenerative diseases. For example, NFKBIE has been shown to interact with the protein Tau, which is involved in the regulation of cell division and growth in the brain. By modulating the activity of Tau, NFKBIE has been shown to play a role in the development of neurodegenerative diseases.

In addition to its potential role as a drug target, NFKBIE also has potential as a biomarker for the diagnosis and monitoring of neurodegenerative diseases. The NFKBIE protein has been shown to be expressed in the brain and has been used as a biomarker for the diagnosis of Alzheimer's disease. Additionally, the NFKBIE protein has been shown to be involved in the regulation of normal brain function, which could be used as a biomarker for the diagnosis and monitoring of other neurodegenerative diseases.

In conclusion, the NFKBIE protein is a potential drug target for the treatment of neurodegenerative diseases due to its involvement in the development and progression of these diseases and its ability to modulate the activity of other proteins involved in these processes. Additionally, NFKBIE has potential as a biomarker for the diagnosis and monitoring of these diseases. Further research is needed to fully understand the role of NFKBIE in the development and progression of neurodegenerative diseases and its potential as a drug and biomarker.

Protein Name: NFKB Inhibitor Epsilon

Functions: Inhibits NF-kappa-B by complexing with and trapping it in the cytoplasm. Inhibits DNA-binding of NF-kappa-B p50-p65 and p50-c-Rel complexes

The "NFKBIE Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NFKBIE comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets